Better treatment outcomes of EGFR-TKIs were shown in females, non-smokers, and patients with lung adenocarcinoma, and thus it is not surprising to observe frequent amplifications (52%) and mutations (83%) of EGFR in our results. The gene discussed is EGFR; the disease is lung adenocarcinoma.